EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Clinical trial NCT06556563 · RECRUITING
Trial details
- NCT number
- NCT06556563
- Sponsor
- NovoCure GmbH
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-03
- Primary completion
- 2029-04-01
- Enrollment
- 741
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.